It has been reported that the inactivation of NFκB-binding activity sensitizes human ovarian cancer cells to cisplatin in vitro  [57] and that the combined therapy of cisplatin with a PI3K inhibitor enhances the apoptotic effect of cisplatin in vivo  [58]. Here, NFKB1 is linked to ovarian carcinoma.